ERBB2 and breast cancer: The results of our study show that molecular subtypes as determined by BluePrint are associated with response to neoadjuvant pertuzumab in stage II and III HER2-positive breast cancer, independent of other clinical variables such as hormone receptor status and HER2 immunohistochemistry score.